Xtalks Webinar: June 18, 20182018-08-21T14:37:43+00:00

Xtalks Webinar: Neoantigens for Personalized Cancer Vaccines:

Comprehensive Identification and Effective Selection

Webinar: June 18, 10:00 AM Pacific Daylight Time 

Developing effective personalized cancer vaccines depends on comprehensively detecting all neoantigens in a tumor sample and then selecting the neoantigens that are most likely to be effective in an individual patient.   This process, especially under the timeline demands of clinical trials or commercial vaccine development, can be incredibly complex. Gaps in sequencing coverage found in standard exome and transcriptome assays can lead to missed neoantigens, and filtering neoantigens often requires incorporating data across multiple assays to make an informed decision.

Personalis developed the ACE ImmunoID platform to overcome these challenges. ACE ImmunoID combines augmented exome and transcriptome assays with advanced bioinformatics to both comprehensively identify neoantigens and provide accurate analytics to help inform the selection of candidate neoantigens.

Topics to be discussed during this webinar will include: 

  • Technical overview of ACE ImmunoID including augmentation and validation
  • Review of bioinformatics deliverables and analytical modules including HLA Typing, Similarity-to-Self, Similarity-to-Known-Antigens, and Tumor Immunogenomics
  • Case study demonstrating ACE ImmunoID’s further utility in biomarker discovery through identifying methods of tumor escape in patients treated with checkpoint modulators
  • Best practices for designing rapid, patient-centric processes for vaccine clinical trials including optimizing sample preparation and integrating lab automation

Who should attend?

Professionals from biopharmaceutical organizations developing neoantigen-based therapeutics including:

Job Functions:

  • Heads of Immuno-Oncology Clinical Development Programs
  • Chief Medical and Scientific Officers
  • Biomarker Specialists
  • Translational Researchers
  • Regulatory Affairs

Areas of Interest:

  • Immuno-oncology
  • Personalized Medicines
  • Neoantigen-based therapeutics (vaccines, adoptive cell therapies)
  • Checkpoint inhibitors and immune modulators

What you will learn

  • Technical overview of ACE ImmunoID including augmentation and validation
  • Review of bioinformatics deliverables and analytical modules including HLA Typing, Similarity-to-Self, Similarity-to-Known-Antigens, Candidate Neoantigen Ranking, and Tumor Immunogenomics
  • Case study demonstrating ACE ImmunoID’s further utility in biomarker discovery through identifying methods of tumor escape in patients treated with checkpoint modulators
  • Best practices for designing rapid, patient-centric processes for vaccine clinical trials including optimizing sample preparation and integrating lab automation

Presenters

Sean Michael Boyle, MS, PhD
Director, Bioinformatics Applications
Personalis, Inc.

Sean is Director of Bioinformatics Applications at Personalis, with broad experience across analysis and interpretation of cancer genomics data.  At Personalis, Sean leads a team focused on development neoantigen prediction, cell free applications, tumor microenvironment analysis, and biomarker analysis for the ACE ImmunoID platform.   His team is also applying these technologies through external scientific collaborations with both academic and industry partners. Prior to Personalis, Sean worked on advancing genomics and personalized genomic medicine, notably with the Dr. Mike Snyder lab at Stanford University, where he developed novel methods for analyzing and interpreting patient samples from both cancer and inherited disease.

Kedar Hastak, MS, PhD
Field Applications Scientist
Personalis, Inc.

Dr. Hastak is a Field Applications Scientist and provides technical support on the Personalis ACE Cancer Products. Prior to joining Personalis, he was a Senior Scientist at Stanford University’s Division of Oncology where he led studies evaluating efficacy of small molecules therapeutics in solid tumors. He trained at the Cleveland Clinic and Stanford University, and received his PhD in field of Cancer Biology from Case Western Reserve University.

View Webinar